We are committed to delivering our strategy and creating value for our shareholders.

Verona Pharma can make real a difference to the COPD market, believes CEO Jan-Anders Karlsson

Jan-Anders Karlsson says the recent strengthening of its management team has given Verona Pharma PLC (LON:VRP) the experience to take its respiratory disease treatment Ensifentrine to market.


Watch Jan-Anders Karlsson on Proactive Investors

Latest News

Latest Events

17 January 2020Regulatory
Holding(s) in Company TR-1: Standard form for notification of major holdings

LONDON, Jan. 17, 2020 (GLOBE NEWSWIRE) -- TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to

13 January 2020Company News, Regulatory
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function Clinically relevant secondary endpoints met, including progressive and statistically significant improvements in quality of life Conference call scheduled

10 January 2020Company News
Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy

Data release and conference call on Monday January 13, 2020 LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, will release results on Monday, January 13, 2020 at 5.00

View all regulatory news

© Verona Pharma plc 2020. All rights reserved